Hvis sådanne inhibitorer forekommer, kan tilstanden komme til udtryk som et utilstrækkeligt klinisk respons.
As with all coagulation factor VIII products, patients are to be monitored for the development of inhibitors that are to be titrated in Bethesda Units (BUs) using the Nijmegen modification of the Bethesda assay. If such inhibitors occur, the condition may manifest itself as an insufficient clinical response.